{
  "ticker": "ANR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967687",
  "id": "02967687",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250709",
  "time": "0919",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmn7kbmr6flj.pdf",
  "summary": "- **Japanese Patent Grant**: GaRP patent granted in Japan, valid until 9 October 2040, joining existing patents in Hong Kong, Australia, and the EU.  \n- **Anti-Obesity Project Progress**: Pre-clinical studies in diet-induced obese mice advanced to treatment challenge phase; initial results expected in ~6 months.  \n- **R&D Tax Incentive**: Application for 2024-2025 income period registered (AusIndustry, 8 July 2025).  \n- **GaRP-IBS Trial**: Commercialisation discussions ongoing after trial success on safety, anxiety reduction, and symptom sub-scores (pain severity/frequency, distension). Primary efficacy endpoint (overall IBS-SSS) not statistically significant.  \n- **Funding**: $350,000 allocated to anti-obesity proof-of-concept studies.  \n\nNo material capital markets actions (e.g., raising, timetable) identified.",
  "usage": {
    "prompt_tokens": 2370,
    "completion_tokens": 185,
    "total_tokens": 2555,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T23:54:08.181743"
}